Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs, …

The World Health Organization (WHO) recommends that countries implement pharmacovigilance
and collect information on active drug safety monitoring (aDSM) and management of …

No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate
to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The …

Background Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common
form of drug resistance, and is associated with failure, relapse, and acquired rifampicin …

No large study to date has ever evaluated the effectiveness, safety and tolerability of
imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-…

Linezolid has been successfully used for treatment of multidrug-resistant tuberculosis (MDR-TB).
However, dose- and duration-related toxicity limit its use. Here, our aim was to search …

Tuberculosis (TB), once considered as a disease of the past generally afflicting poor people,
still claims 1.5 million lives annually [1]. Although 86% of patients with drug susceptible TB …

Introduction Dosing of antibiotics in people with cystic fibrosis (CF) is challenging, due to
altered pharmacokinetics, difficulty of lung tissue penetration, and increasing presence of …

Background Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus
disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of …

In December 2022 World Health Organization released a new treatment for multidrug-resistant/rifampicin-resistant
tuberculosis (MDR/RR-TB) guideline. The main novelty of this update …